singl
dose
vaccin
mycoplasma
bovi
pneumonia
inactiv
saponin
inocul
subcutan
weekold
calv
calv
challeng
week
later
virul
strain
bovi
two
occas
within
h
use
aerosol
rout
calv
monitor
clinic
sign
serolog
respons
post
mortem
week
challeng
vaccin
shown
highli
immunogen
calv
caus
advers
effect
vaccin
calv
show
clinic
sign
unvaccin
calv
develop
sign
pneumonia
signific
decreas
bodi
weight
gain
unvaccin
calv
compar
vaccin
signific
increas
lung
lesion
rectal
temperatur
unvaccin
calv
vaccin
also
reduc
spread
bovi
intern
organ
conclus
bovi
vaccin
produc
signific
level
protect
larg
virul
challeng
crown
mycoplasma
bovi
primari
caus
calf
pneumonia
arthriti
mastiti
keratoconjunct
condit
estim
cost
us
cattl
industri
least
million
dollar
mortal
set
back
loss
annual
countri
free
diseas
worldwid
movement
cattl
europ
bovi
believ
respons
outbreak
calf
pneumonia
control
larg
restrict
manag
practis
improv
ventil
reduc
stock
densiti
chemotherapi
howev
long
known
bovi
like
mycoplasma
natur
resist
mani
antibiot
lack
cell
wall
furthermor
last
decad
evid
accumul
bovi
becom
resist
antibiot
tradit
effect
includ
tetracyclin
tilmicosin
spectinomycin
result
increasingli
poor
respons
treatment
use
vaccin
would
seem
ration
approach
control
diseas
caus
exacerb
bovi
first
attempt
develop
vaccin
calf
pneumonia
report
howard
et
al
show
quadrival
formalis
kill
vaccin
incorpor
bovi
respiratori
pathogen
compris
respiratori
syncyti
viru
parainfluenza
type
viru
mycoplasma
dispar
effect
protect
natur
outbreak
bovin
respiratori
diseas
howev
work
continu
vaccin
vaccin
prepar
formalininactiv
strain
bovi
mannheimia
haemolytica
taken
target
herd
reduc
loss
pneumonia
cost
treatment
newli
introduc
feedlot
calv
attempt
use
formalin
inactiv
mycoplasma
infect
larg
unsuccess
produc
transient
protect
probabl
damag
effect
chemic
antigen
composit
mycoplasma
one
report
use
formalin
inactiv
bovi
vaccin
actual
led
increas
diseas
follow
challeng
vaccin
calv
compar
shamvaccin
anim
modern
approach
vaccin
also
disappoint
experiment
vaccin
compos
partial
purifi
membran
protein
bovi
also
increas
pneumon
patholog
use
saponin
extract
bark
south
american
tree
guillaia
saponaria
adjuv
well
known
shown
boost
immun
respons
immunogen
howev
also
effect
rapidli
lyse
cholesterol
rich
membran
mycoplasma
vaccin
seriou
goat
diseas
contagi
caprin
pleuropneumonia
ccpp
caus
mycoplasma
inactiv
saponin
immedi
prior
inocul
provid
signific
protect
experiment
infect
saponis
vaccin
small
rumin
mycoplasma
infect
contagi
agalactia
prove
protect
heat
kill
formalin
inactiv
vaccin
report
result
experiment
vaccin
contain
saponis
bovi
cell
prevent
infect
larg
challeng
virul
geograph
differ
strain
bovi
three
fourweekold
male
calv
obtain
commerci
dairi
herd
holsteinfriesian
breed
consist
cow
similar
number
grow
heifer
cattl
introduc
year
newborn
calv
receiv
colostrum
dam
within
h
birth
first
day
calv
fed
milk
dam
receiv
milk
replac
place
individu
box
open
air
week
calv
given
premix
lucerna
hay
quantum
sati
free
access
water
parent
herd
routin
vaccin
infecti
bovin
rhinotrach
viru
bovin
viral
diarrhoea
overt
clinic
sign
pneumonia
seen
herd
evid
bovi
nasal
caviti
sera
calv
measur
serolog
cultur
pcr
techniqu
see
section
bovirhini
pasteurella
multicoda
repres
normal
bovin
flora
detect
nasal
caviti
sever
calv
strain
bovi
design
kept
c
isol
uk
lung
calf
grown
eaton
medium
h
c
subcultur
fresh
medium
h
mycoplasma
centrifug
g
min
resuspend
wash
phosphat
buffer
salin
ph
cell
centrifug
resuspend
origin
volum
wash
cell
ad
mgml
filter
sterilis
saponin
sigma
pool
incub
h
c
saponis
cell
place
c
titr
wash
cell
coloni
form
unit
cfu
ml
protein
content
estim
approxim
mgml
vaccin
plate
onto
blood
agar
check
bacteri
contamin
eaton
medium
ensur
inactiv
mycoplasma
three
subcultur
everi
day
inactiv
cell
perform
plate
everi
subcultur
mycoplasma
bacteria
detect
bovi
strain
isol
calf
hungari
propag
medium
b
h
titr
cfu
ml
calv
randomli
alloc
four
group
one
week
vaccin
three
group
transport
experiment
accommod
institut
budapest
group
hous
separ
experi
calv
offer
l
milk
replac
kg
premix
kg
hay
twice
day
fourth
vaccin
group
remain
unchalleng
farm
observ
advers
reaction
monitor
serolog
month
three
week
vaccin
calv
group
b
challeng
broth
cultur
bovi
strain
see
section
aerosol
infect
two
success
day
calv
kept
week
examin
post
mortem
begin
end
experi
nasal
swab
taken
calf
detect
mycoplasma
medium
b
pcr
bovi
screen
p
multocida
haemolytica
haemophilu
somnu
carri
use
convent
bacteriolog
techniqu
post
mortem
nasal
caviti
trachea
lung
lung
wash
peribronchi
lymph
node
liver
spleen
kidney
carpal
tarsal
joint
cultur
mycoplasma
bacteriolog
examin
perform
lung
lung
fluid
vaccin
challeng
day
challeng
sera
calf
test
igg
antibodi
bovi
use
elisa
hoechst
roussel
veterinari
diagnost
liebefeldbern
switzerland
sera
taken
calv
begin
end
experi
also
test
antibodi
bovin
viral
diarrhoea
infecti
bovin
rhinotrach
viru
bovin
respiratori
viru
adenoviru
type
ii
coronaviru
parainfluenza
viru
type
rectal
temperatur
calv
measur
period
vaccin
site
vaccin
examin
calv
also
score
gener
clinic
sever
gross
patholog
lesion
inner
organ
score
percentag
lung
pneumon
lesion
also
estim
detail
patholog
assess
given
tabl
addit
lung
lesion
score
macroscop
follow
lesion
degre
consolid
left
right
apic
left
right
cardiac
accessori
lobe
score
cranial
lobe
left
right
diaphragmat
lobe
score
intermedi
lobe
lesion
also
assess
histolog
interstiti
pneumonia
lymphohistiocyt
bronchiti
cattarrh
pneumonia
bovi
detect
nasal
caviti
calv
time
challeng
post
mortem
excep
tion
nasal
caviti
bovi
isol
organ
significantli
fewer
vaccin
calv
nonvaccin
calv
tabl
bovi
also
isol
joint
two
lame
nonvaccin
calv
evid
infect
haemolytica
h
somnu
lung
calv
throughout
experi
p
multocida
isol
sever
calv
group
ac
begin
experi
calv
end
corynebacterium
speci
also
found
sporad
begin
end
data
shown
neither
two
speci
found
lung
calv
result
elisa
bovi
antibodi
shown
fig
antibodi
detect
non
vaccin
control
group
c
throughout
experi
two
vaccin
group
antibodi
detect
week
mean
antibodi
level
detect
elisa
still
high
posit
control
month
later
group
remain
farm
clinic
evid
natur
respiratori
diseas
vaccin
nonvaccin
calv
farm
group
b
seroconvert
rapidli
challeng
reach
level
group
end
experi
calv
serolog
posit
infecti
bovin
rhinotrach
parainfluenza
viru
increas
titr
experi
evid
presenc
virus
advers
sign
vaccin
seen
site
inocul
palpat
reveal
swell
tissu
three
calv
two
vaccin
group
disappear
day
clinic
sign
pneumonia
seen
group
b
day
challeng
follow
shortli
cough
nasal
discharg
calv
group
show
mild
clinic
sign
statist
differ
subject
score
vaccin
non
vaccin
b
group
tabl
clinic
diseas
seen
control
group
c
time
two
calv
group
b
develop
clinic
arthriti
week
show
accumul
fluid
tarsal
carpal
joint
accompani
pain
increas
joint
temperatur
calv
group
becam
affect
feed
refus
notic
group
b
statist
higher
group
b
tabl
statist
higher
rectal
temperatur
seen
group
b
day
challeng
continu
day
data
shown
averag
bodi
weight
group
b
c
differ
significantli
week
follow
challeng
howev
week
significantli
lower
weight
gain
p
record
group
b
compar
group
c
fig
lung
damag
assess
percentag
lung
affect
significantli
higher
challeng
group
b
vaccin
group
tabl
smaller
signific
differ
group
control
c
lung
lesion
score
significantli
higher
group
b
either
group
p
group
c
p
smaller
signific
differ
group
c
p
histolog
lesion
score
interstiti
pneumonia
thicken
septa
lymphoid
cell
macrophag
lymphohistiocyt
bronchiti
catarrh
bronchopneumonia
accompani
accumul
intraalveolar
intrabronchila
exud
consist
neutrophil
macrophag
lymphocyt
coagul
necrosi
pleurisi
well
total
histolog
score
significantli
lower
vaccin
challeng
group
nonvaccin
challeng
group
b
tabl
signifi
cant
differ
group
c
apart
lymphohistiocyt
bronchiti
score
vaccin
exist
major
respiratori
pathogen
cattl
infecti
bovin
rhinotrach
bovin
viral
diarrhoea
respiratori
syncyti
viru
usual
provid
satisfactori
level
protect
lack
commerci
vaccin
bovi
probabl
reflect
inconclus
result
previou
experi
includ
exacerb
diseas
seen
follow
vaccin
furthermor
need
specialist
expens
facil
diagnos
mycoplasma
infect
led
report
mycoplasma
diseas
give
rise
still
pervas
view
amongst
mani
veterinarian
role
bovi
respiratori
diseas
complex
proven
import
bovi
shown
conclus
follow
introduct
northern
republ
ireland
earli
rapidli
becam
major
caus
respiratori
diseas
well
frequent
caus
mastiti
arthriti
britain
franc
bovi
believ
respons
calf
pneumonia
usa
author
believ
may
involv
chronic
calf
pneumonia
denmark
increas
case
also
report
final
eas
bovi
caus
pneumonia
calv
experiment
demonstr
import
field
present
work
result
work
report
indic
even
singl
dose
vaccin
prepar
saponis
bovi
cell
may
provid
effect
control
mycoplasmainduc
calf
pneumonia
even
geograph
divers
strain
present
case
addit
vaccin
appear
safe
highli
immunogen
calv
test
month
immunis
high
level
humor
immun
evid
also
provid
vaccin
may
also
protect
arthriti
though
work
need
confirm
would
expect
bovi
vaccin
would
also
reduc
infect
ubiquit
bacteria
haemolytica
p
multocida
h
somnu
bovi
primari
underli
caus
impair
host
defenc
system
success
use
saponin
vaccin
alreadi
demonstr
mycoplasma
infect
ccpp
contagi
agalactia
effect
must
associ
fact
appar
preserv
major
antigen
seen
untreat
whole
cell
kensil
et
al
specul
high
level
protect
seen
use
saponin
vaccin
mice
may
caus
abil
saponin
induc
isotyp
profil
similar
seen
natur
immun
bacteri
infect
known
effect
saponin
alon
would
calv
challeng
present
experi
although
brief
stimul
immun
system
particular
respons
may
expect
b
morein
person
commun
howev
highli
unlik
led
level
protect
seen
saponis
vaccin
saponin
also
report
inactiv
mycoplasma
rapidli
suggest
improv
could
made
vaccin
prepar
describ
howev
clear
balanc
must
struck
reduc
concentr
prevent
advers
reaction
although
mild
reaction
seen
retain
effect
adjuv
report
resist
bovi
isol
commonli
use
antibiot
last
year
strongli
suggest
vaccin
may
provid
effect
approach
control
increasingli
import
diseas
vaccin
administ
immedi
matern
antibodi
wane
week
age
may
interfer
vaccin
antibodi
level
could
monitor
conveni
elisa
